Reports Q3 revenue $57,000, consensus $70,000. “Onconova has made excellent progress in the third quarter of 2023. Starting with our lead program, narazaciclib, a differentiated inhibitor of multiple kinases including CDK4/6, we advanced the registrational trial preparations in the first indication, for patients with low grade endometrioid endometrial cancer (LGEEC). CDK4/6 inhibitors have substantially changed the face of cancer care for the better and become a multibillion-dollar drug class. We believe narazaciclib has the potential to be differentiated by potently targeting proteins putatively involved in the resistance pathways of cancer cells that the approved agents fail to significantly inhibit,” said Steve Fruchtman, President and Chief Executive Officer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ONTX:
- Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
- ONTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
- Onconova’s ASH poster to focus on narazaciclib in MCL
- Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL